All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

Qualit-E-SpeakPharma-Insert

X

Find Dermatology Drugs in Phase I/II Clinical Development

A collaboration with SCORR Marketing

All Data

Filters

refresh

×

FILTER DATA :

Country

News Type

Company

Product Type

Deal Size

refresh

Product Type

Companies

Forte Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Tocagen and Forte Biosciences Announce Merger

Contact the Supplier

Lead Product(s): FB-401

Therapeutic Area: Dermatology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Alger

Deal Size: $25.0 million Upfront Cash: Undisclosed

Deal Type: Merger February 19, 2020

Details:

The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis.

Krystal Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Drug Discovery Chemistry

Participation Not Confirmed

Update your events

Krystal Biotech investing up to $90M on facility for its gene therapies

Contact the Supplier

Lead Product(s): B-VEC

Therapeutic Area: Dermatology

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Undisclosed

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Investment January 24, 2020

Details:

Krystal Biotech intends to make the clinical material for an upcoming phase 3 trial of B-VEC at its Ancoris facility and anticipates starting the trial in Q1 2020.